858 related articles for article (PubMed ID: 21955617)
1. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis.
Zweers MC; de Boer TN; van Roon J; Bijlsma JW; Lafeber FP; Mastbergen SC
Arthritis Res Ther; 2011; 13(5):239. PubMed ID: 21955617
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis.
Mastbergen SC; Marijnissen AC; Vianen ME; Zoer B; van Roermund PM; Bijlsma JW; Lafeber FP
Rheumatology (Oxford); 2006 Apr; 45(4):405-13. PubMed ID: 16287921
[TBL] [Abstract][Full Text] [Related]
3. Augmented chondroprotective effect of coadministration of celecoxib and rebamipide in the monosodium iodoacetate rat model of osteoarthritis.
Moon SJ; Park JS; Jeong JH; Yang EJ; Park MK; Kim EK; Park SH; Kim HY; Cho ML; Min JK
Arch Pharm Res; 2013 Jan; 36(1):116-24. PubMed ID: 23338062
[TBL] [Abstract][Full Text] [Related]
4. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study.
Mastbergen SC; Bijlsma JW; Lafeber FP
Osteoarthritis Cartilage; 2005 Jun; 13(6):519-26. PubMed ID: 15922186
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib does not affect the release of hyaluronic acid in end stage osteoarthritic joints.
Takahashi D; Majima T; Onodera T; Kasahara Y; Inoue M; Irie T; Kasemura T
Mod Rheumatol; 2013 Sep; 23(5):934-8. PubMed ID: 23001685
[TBL] [Abstract][Full Text] [Related]
6. Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte.
Ou Y; Tan C; An H; Jiang D; Quan Z; Tang K; Luo X
Med Sci Monit; 2012 Jun; 18(6):BR247-52. PubMed ID: 22648246
[TBL] [Abstract][Full Text] [Related]
7. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review.
Nakata K; Hanai T; Take Y; Osada T; Tsuchiya T; Shima D; Fujimoto Y
Osteoarthritis Cartilage; 2018 Oct; 26(10):1263-1273. PubMed ID: 29890262
[TBL] [Abstract][Full Text] [Related]
8. Lack of a chondroprotective effect of cyclooxygenase 2 inhibition in a surgically induced model of osteoarthritis in mice.
Fukai A; Kamekura S; Chikazu D; Nakagawa T; Hirata M; Saito T; Hosaka Y; Ikeda T; Nakamura K; Chung UI; Kawaguchi H
Arthritis Rheum; 2012 Jan; 64(1):198-203. PubMed ID: 21905007
[TBL] [Abstract][Full Text] [Related]
9. Development and reliability of a multi-modality scoring system for evaluation of disease progression in pre-clinical models of osteoarthritis: celecoxib may possess disease-modifying properties.
Panahifar A; Jaremko JL; Tessier AG; Lambert RG; Maksymowych WP; Fallone BG; Doschak MR
Osteoarthritis Cartilage; 2014 Oct; 22(10):1639-50. PubMed ID: 25278073
[TBL] [Abstract][Full Text] [Related]
10. [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
Mateos JL
Drugs Today (Barc); 2010 Feb; 46 Suppl A():1-25. PubMed ID: 20224826
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.
Antoniou K; Malamas M; Drosos AA
Expert Opin Pharmacother; 2007 Aug; 8(11):1719-32. PubMed ID: 17685888
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
McCormack PL
Drugs; 2011 Dec; 71(18):2457-89. PubMed ID: 22141388
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intra-articular injection of celecoxib in a rabbit model of osteoarthritis.
Jiang D; Zou J; Huang L; Shi Q; Zhu X; Wang G; Yang H
Int J Mol Sci; 2010 Oct; 11(10):4106-13. PubMed ID: 21152323
[TBL] [Abstract][Full Text] [Related]
14. The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment.
de Boer TN; Huisman AM; Polak AA; Niehoff AG; van Rinsum AC; Saris D; Bijlsma JW; Lafeber FJ; Mastbergen SC
Osteoarthritis Cartilage; 2009 Apr; 17(4):482-8. PubMed ID: 18926729
[TBL] [Abstract][Full Text] [Related]
15. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
16. Controlled release of celecoxib inhibits inflammation, bone cysts and osteophyte formation in a preclinical model of osteoarthritis.
Tellegen AR; Rudnik-Jansen I; Pouran B; de Visser HM; Weinans HH; Thomas RE; Kik MJL; Grinwis GCM; Thies JC; Woike N; Mihov G; Emans PJ; Meij BP; Creemers LB; Tryfonidou MA
Drug Deliv; 2018 Nov; 25(1):1438-1447. PubMed ID: 29890922
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R
J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Goldenberg MM
Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
[TBL] [Abstract][Full Text] [Related]
19. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Fleischmann R; Sheldon E; Maldonado-Cocco J; Dutta D; Yu S; Sloan VS
Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
